Hardman & Co Research: Shield Therapeutics (STX): Looking to accelerate positive signals in the US

Hardman & Co Research on Shield Therapeutics (STX):

Looking to accelerate positive signals in the US

Shield Therapeutics (Shield) is a commercial-stage pharma company delivering specialty products that address patients unmet medical needs, with an initial focus on iron deficiency (ID). Following launch of Accrufer® in the US in July 2021, the initial challenge was to greatly improve market awareness of its differentiating features as an oral ID drug. The US market offers enormous potential, but the uptake has been slower than the market had anticipated. While considerable progress has been made, in order to accelerate prescription (Rx) growth and obtain sales traction, more capital will be required by the end of 2022.

Please click on the link below for the full report:

https://hardmanandco.com/research/corporate-research/looking-to-accelerate-positive-signals-in-the-us/

If you are interested in meeting the company, you can register your interest by clicking on the above link.

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.